20 years of make-up neglect proves a skin-credible mistake
Compiled by FAZLEENA AZIZ, TAN SIN CHOW AND R. ARAVINTHAN
AFTER 20 years of not properly removing her make-up, a 37-year-old woman in Jilin city, China, began suffering from red, itchy and hardened skin.
Sin Chew Daily reported that the woman, known only as Gao, began using makeup at 15 and admitted to almost never removing it properly since. At best, she would rinse her face with water before going to bed.
Her face recently became severely swollen and inflamed. Instead of seeing a dermatologist, she went to a cosmetic clinic and got a 'skin booster injection' (also known as mesotherapy).
But afterwards, her face became stiff, the redness deepened into a purplish tone, and the heat and itchiness worsened.
According to the news report, leftover make-up and dirt can irritate the skin, causing redness, itchiness or even allergic reactions such as swelling and blisters.
Some netizens questioned the story's authenticity, suggesting the woman's face showed signs of cosmetic surgeries, and it was unlikely she would have been allowed to have make-up on during surgery.
Others said her symptoms were consistent with viral infections or allergic reactions following mesotherapy.
> Veteran Hong Kong actor Alex Man, 67, has been relying on nightclub performances and commercial events to make a living.
Now living in China, his mental and physical health have been a source of concern among fans, Oriental Daily reported.
In a recent public appearance, Man was seen limping.
Despite his poor health, Man continues to work to support his family.
In footage of one of his recent commercial appearances, he is seen performing as a drummer during a lion dance show. Despite playing the drums energetically, his gait appeared laboured.
(The above articles are compiled from the vernacular newspapers (Bahasa Malaysia, Chinese and Tamil dailies). As such, stories are grouped according to the respective language/medium. Where a paragraph begins with a >, it denotes a separate news item.)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
9 hours ago
- The Star
20 years of make-up neglect proves a skin-credible mistake
Compiled by FAZLEENA AZIZ, TAN SIN CHOW AND R. ARAVINTHAN AFTER 20 years of not properly removing her make-up, a 37-year-old woman in Jilin city, China, began suffering from red, itchy and hardened skin. Sin Chew Daily reported that the woman, known only as Gao, began using makeup at 15 and admitted to almost never removing it properly since. At best, she would rinse her face with water before going to bed. Her face recently became severely swollen and inflamed. Instead of seeing a dermatologist, she went to a cosmetic clinic and got a 'skin booster injection' (also known as mesotherapy). But afterwards, her face became stiff, the redness deepened into a purplish tone, and the heat and itchiness worsened. According to the news report, leftover make-up and dirt can irritate the skin, causing redness, itchiness or even allergic reactions such as swelling and blisters. Some netizens questioned the story's authenticity, suggesting the woman's face showed signs of cosmetic surgeries, and it was unlikely she would have been allowed to have make-up on during surgery. Others said her symptoms were consistent with viral infections or allergic reactions following mesotherapy. > Veteran Hong Kong actor Alex Man, 67, has been relying on nightclub performances and commercial events to make a living. Now living in China, his mental and physical health have been a source of concern among fans, Oriental Daily reported. In a recent public appearance, Man was seen limping. Despite his poor health, Man continues to work to support his family. In footage of one of his recent commercial appearances, he is seen performing as a drummer during a lion dance show. Despite playing the drums energetically, his gait appeared laboured. (The above articles are compiled from the vernacular newspapers (Bahasa Malaysia, Chinese and Tamil dailies). As such, stories are grouped according to the respective language/medium. Where a paragraph begins with a >, it denotes a separate news item.)
The Sun
2 days ago
- The Sun
Hong Kong Baptist University Showcases World-Leading Research in Digital Health & Systems Medicine at THE Global Sustainable Development Congress 2025
ISTANBUL, TURKEY - Media OutReach Newswire - 19 June 2025 – Hong Kong Baptist University (HKBU) illuminated the path to global well-being as the Global Health Innovation Partner and sponsor of the Health and Wellbeing Track at the Times Higher Education (THE) Global Sustainable Development Congress (GSDC) 2025, from June 16-19, 2025. At this gathering of over 5,000 global thought leaders, HKBU presented its comprehensive, interdisciplinary strategy for health and well-being, spearheaded by its Health & Drug Discovery research cluster. Firmly aligned with the United Nations' Sustainable Development Goals, HKBU's vision for health transformation drives from data to actionable insight. It comprehensively integrates mental and digital well-being, real-time analytics, and innovative interdisciplinary approaches. This includes blending traditional Chinese Medicine with cutting-edge sciences like chemical biology and data analytics, complemented by advancements in environmental, physical, and social sciences. A Hub for Holistic Health A highlight of HKBU's presence was the 6,000-square-foot 'Well-being Zone', thoughtfully designed to embody the principle that health is holistic and interconnected. This innovative Zone brought the concept of interdisciplinarity to a global audience by seamlessly integrating diverse fields, from martial arts and mindfulness to cutting-edge digital health monitoring: • Interdisciplinary Movement & Mindfulness: Tai Chi, Baduanjin and Mindfulness Karate sessions demonstrated HKBU's 'exercise is medicine' philosophy. • Real-Time Digital Well-being Research: Participants had the unique opportunity to contribute live data for Professor Christy Cheung's pioneering studies, which explore how digital tools can effectively measure mindfulness and enhance overall well-being. • Expert-Led Talks: Distinguished HKBU academics presented cutting-edge interdisciplinary research. Topics included critical global health trends, advancements in mental well-being, and innovative applications of Chinese Medicine and AI in modern healthcare. • Reflection & Rejuvenation Spaces: Thoughtfully curated 'chill-out' relaxation areas, massage corners and a juice bar provided spaces for participants to experience a reboot of the body and the mind. Highlighting HKBU's research strength in the transformative power of technology for global health, Professor Martin Wong, Provost & Chair Professor of Computer Science, emphasised, 'HKBU's recent top-50 global ranking in databases, design automation, and artificial intelligence underscores our collaborative ethos. By integrating advanced AI methodologies with clinical, pharmaceutical and social-science expertise, we are optimising diagnostics, accelerating drug discovery and enhancing surgical assistance. This interdisciplinary approach reinforces Hong Kong's reputation as a global hub for cutting-edge research and higher education.' Professor Lyu Aiping, Vice-President (Research & Development), highlighted HKBU's strategic edge, 'Hong Kong is uniquely positioned to lead East–West integration in digital health and systems medicine. HKBU combines the rigour of life sciences with robust Chinese Medicine research, underpinned by advanced data analytics. This powerful synergy enables us to tackle complex health disparities at biological, social, and environmental levels, and build resilient, equitable health systems to meet future global challenges.' In addition to numerous insightful presentations and the interactive experiences, HKBU Provost Professor Martin Wong gave a keynote at the session entitled 'Reframing Sustainability through the Lens of Chinese Heritage and Innovation' convened by the China Education Association for International Exchange. HKBU also released the 'Evolving Legacy: Decoding the Scientific Trajectory of Chinese Medicine' Report ( in collaboration with Elsevier. This report examines the development and evolving research landscape of Chinese Medicine and its growing influence on modern healthcare.
New Straits Times
3 days ago
- New Straits Times
China pharma projects disrupted by Sino-US tensions
SHANGHAI: Drug research and development firms in China including WuXi AppTec and WuXi Biologics are changing project plans, stockpiling supplies and discussing testing locally, said sources with knowledge of the matter, as they seek to mitigate the impact of US-China trade tensions. China's sprawling pharmaceutical research and manufacturing sector serves global drug giants such as Pfizer and AstraZeneca with a low-cost development model that often uses imported clinical samples, equipment, chemicals and other materials to conduct work. Fears of delay in access to US supply chains and raised import tariffs are spurring biotech and pharmaceutical companies to avoid, pause or consider delaying the start of projects, according to three sources. They are also discussing testing US clinical samples in the US, instead of sending them to China for further research, a move that could increase costs, and requesting additional supplies for backup, three other sources said. The six sources who spoke to Reuters are director or executive-level employees involved in various aspects of the industry in China including research and development, manufacturing and supply chains. All but two agreed to speak only on condition of anonymity because of concerns about effects on fundraising plans or they were not authorised to speak to media. The developments have not been reported previously. US and Chinese officials said last week they had agreed on a framework to put a May trade truce back on track and remove China's export restrictions on rare earths, but offered little sign of a durable resolution to longstanding trade differences that have affected products ranging from semiconductors and jet engines to medical equipment and pharmaceuticals. "What kind of long-term policy it could be, you know, what kind of tariff would it be in half a year, in one year... nobody knows. And that's the problem. That's what makes everybody worry and nervous," said Chen Gong, co-founder of NeuExcell Therapeutics, a biotech with its main operations in Suzhou. He said the US-China trade tensions had made him more cautious about investing in a clinical trial and the company would delay its start if it did not have sufficient funding. Reliance on US imports has come into particular focus as trade tensions escalate. In 2024, the US exported diagnostic and laboratory reagents to China valued at about US$1.4 billion and prepared culture media for the development or maintenance of microorganisms worth about US$125 million, U.N. Comtrade data showed. In a sign of the importance of some of the imports and the damaging effect disruption could have on China's healthcare industry, some US-made goods including diagnostic reagents from Germany's Siemens Healthineers were exempted from raised Chinese tariffs, that company said in May. China raised its tariffs on US imports to as much as 125 per cent though it has since reduced that to 10 per cent while it works out a more permanent trade deal. HIGHER COSTS, DELAYS WuXi AppTec and a Chinese biotechnology firm that was its research client agreed in May to switch US-made reagents they had been using for a Hepatitis B virus pre-clinical research project into non-U.S. versions due partly to concerns about higher costs from tariffs, a source at the client company said. The project had been temporarily paused during the discussions, which began prior to May, the source said. WuXi AppTec said it makes "every effort to avoid disruptions or delays in the delivery of services to customers." Since April, at least 17 Chinese biotech and pharmaceutical clients have contacted Chinese cell culture media manufacturer JS Biosciences asking it to keep locally-made backup raw materials for production because they were concerned about cost increases or the inability to access foreign supplies, the firm's CEO Luo Shun said. "If they have a product made by us, and we rely on the foreign raw material supply and that raw material will increase in price or is never going to come, obviously it will impact their manufacturing of those life-saving drugs. So obviously, that's their primary concern," Luo said. Another Chinese drug research and development firm decided not to provide a quotation to a foreign pharmaceutical company interested in hiring it for protein drug manufacturing, due to delays in obtaining necessary US-made culture medium from a US subsidiary of Japan's Fujifilm, a source at the Chinese firm said. The potential client would likely not have accepted waiting on imports of new supplies into China, which would typically take two to four months, the source said. A Fujifilm Holdings America Corporation spokesperson said Fujifilm Biosciences, one of its life science business units, has made significant investments to build a robust global manufacturing network so that it could navigate any challenges or disruptions, without elaborating on its supply issue involving China. STOCKPILING, US TESTING After China announced a large rise in tariffs for US imports in April, WuXi Biologics placed a bigger-than-normal order for reagents made in the US with a supplier because it was not sure how long that policy action would continue, said a source at the supplier. WuXi Biologics did not respond to requests for comment. Concerns about the potential for US export restrictions led China's Innovent Biologics and multinational BeOne Medicines to discuss with Massachusetts-headquartered Thermo Fisher Scientific the prospect of not sending US clinical samples to China, said a source at the US company. Testing US samples in-country instead of in China would be more expensive, the source said.
